federal enforcement actions, filings and court records, from official sources

••• ⚠️ Newsticker presented by CFExclusion.com ⚠️ ••• 🚨 FRAUD WATCH — Federal authorities announced charges against 16 noncitizens in alleged election-related crimes, including illegal voting and fraudulent voter registration; defendants remain presumed innocent.  • 🤖 AI SECURITY — Researchers report autonomous AI agents attempting hacking techniques against government websites, while malicious AI tools are increasingly being used in cyberattacks.  • 💻 ONLINE THEFT — The FBI says multiple suspects have been arrested in the ShinyHunters data-theft investigation following attacks involving stolen information and extortion.  • 🇺🇸 TRUMP — Trump announced a federal “Super Intelligence Force” to coordinate America’s AI strategy and maintain U.S. technological leadership.  • 🏛️ POLITICS — With one month until the midterms, control of Congress is tightening into a major national battle.  • 🔎 AI SCREENING — As fraud, stolen identities and automated attacks accelerate, AI-based scre

Records through Monday, October 12, 2026 DOJ · SEC · FTC · FDA · CFPB · CFTC · FINRA · OCC · Federal Register · CourtListener · SCOTUSblog

U.S. Food and Drug Administration · FDA enforcement report entry

FDA Class II: Fresenius Kabi USA, LLC — Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vial

The U.S. Food and Drug Administration listed this entry in its enforcement reports on July 29, 2026. The source link opens the FDA’s recalls, market withdrawals and safety alerts page.

Read the official source on fda.gov →

Issued by: U.S. Food and Drug Administration
Document type: FDA enforcement report entry
Date: July 29, 2026
First recorded by CourtPulse: August 4, 2026 · all records that day
Category: FDA action (assigned by CourtPulse)

CourtPulse lists public records with a link to the official source. The title is shown as the source published it; this page adds no commentary.

More from U.S. Food and Drug Administration, within 7 days

FDA Class II: Major Pharmaceuticals — Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per Jul 29, 2026 · FDA enforcement report entry
FDA Class II: Major Pharmaceuticals — Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) unit dose blisters per car Jul 29, 2026 · FDA enforcement report entry
FDA Class II: Ascend Laboratories, LLC — Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only, Manufactur Jul 29, 2026 · FDA enforcement report entry
FDA Class II: Rohto-Mentholatum (Vietnam) Co., Ltd. — Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 80 0.2%), Sterile Jul 29, 2026 · FDA enforcement report entry
FDA Class II: Fresenius Kabi USA, LLC — Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single Dose Vials, 5 mL per via Jul 29, 2026 · FDA enforcement report entry
FDA Class II: Major Pharmaceuticals — Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per c Jul 29, 2026 · FDA enforcement report entry

Get records like this one daily by email →